BIOLIFE SOLUTIONS INC
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
BLFS$38.61+3.5%Stored close · as of Oct 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31 | |||
|---|---|---|---|
| (In thousands, except per share and share data) | 2024 | 2023 | 2022 |
| Product revenue | $76,028 | $68,968 | $71,943 |
| Service revenue | 160 | 349 | 73 |
| Rental revenue | 6,066 | 6,538 | 4,223 |
| Total product, service, and rental revenue | 82,254 | 75,855 | 76,239 |
| Costs and operating expenses: | |||
| Cost of product revenue (exclusive of intangible assets amortization) | 24,502 | 26,557 | 24,970 |
| Cost of service revenue (exclusive of intangible assets amortization) | 52 | — | — |
| Cost of rental revenue (exclusive of intangible assets amortization) | 4,029 | 3,365 | 4,358 |
| General and administrative | 40,541 | 43,264 | 33,255 |
| Sales and marketing | 9,610 | 12,709 | 11,672 |
| Research and development | 7,912 | 12,073 | 8,671 |
| Intangible asset amortization | 2,737 | 3,520 | 3,990 |
| Change in fair value of contingent consideration | — | (2,193) | (4,754) |
| Total operating expenses | 89,383 | 99,295 | 82,162 |
| Operating loss | (7,129) | (23,440) | (5,923) |
| Other (expense) income: | |||
| Interest expense, net | (719) | (1,449) | (284) |
| Other income | 497 | 1,303 | 662 |
| Change in fair value of investments | (4,074) | — | 697 |
| Gain on settlement of Global Cooling escrow | — | 5,115 | — |
| Total other (expense) income, net | (4,296) | 4,969 | 1,075 |
| (Loss) income from continuing operations before income tax benefit | (11,425) | (18,471) | (4,848) |
| Income tax benefit | 38 | 24 | 5,236 |
| (Loss) income from continuing operations | (11,387) | (18,447) | 388 |
| Discontinued operations: | |||
| Loss from discontinued operations before income tax expense | (8,665) | (49,362) | (139,979) |
| Income tax expense | (132) | (193) | (214) |
| Loss from discontinued operations | (8,797) | (49,555) | (140,193) |
| Net loss | $(20,184) | $(68,002) | $(139,805) |
| Loss per share - Basic: | |||
| Continuing operations | $(0.25) | $(0.42) | $0.01 |
| Discontinued operations | $(0.19) | $(1.13) | $(3.30) |
| Net loss | $(0.44) | $(1.55) | $(3.29) |
| Loss per share - Diluted: | |||
| Continuing operations | $(0.25) | $(0.42) | $0.01 |
| Discontinued operations | $(0.19) | $(1.13) | $(3.26) |
| Net loss | $(0.44) | $(1.55) | $(3.25) |
| Weighted average shares used to compute net loss per share attributable to common shareholders: | |||
| Basic | 46,067,073 | 43,719,185 | 42,481,027 |
| Diluted | 46,067,073 | 43,719,185 | 43,073,473 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.